OBJECTIVE: Treatment and follow-up are controversial in patients whose thyroid fine needle aspiration biopsy (FNAB) is reported as atypia of undetermined significance and follicular lesion of uncertain significance (AUS/FLUS). We aimed the efficacy of the American College of Radiology Thyroid Imaging, Reporting and Data System (ACR TI-RADS) in preventing unnecessary thyroidectomies in patients with FNAB cytology results as AUS/FLUS.

METHODS: In Bolu Abant Izzet Baysal University General Surgery Clinic, case series between 2017 and 2020 were analyzed with thyroid operated. Grouping was made according to the result of postoperative pathology: those with benign results after postoperative pathology were classified as Group 1, and those with malignant results after postoperative pathology were classified as Group 2.

RESULTS: As a result, 66 patients were found to be AUS/FLUS. A total of 28.8% of AUS/FLUS patients have been determined with cancer. In the statistical analysis of the ACR TI-RADS score between the groups, the ACR TI-RADS score in Group 1 patients (3.36) (SD 0.87) was significantly lower than that in Group 2 patients (4.11) (SD 1.04) (p=0.003). The distribution of the ACR TI-RADS scores of the patients in Group 2 was TR2: 2 (15.4%) patients, TR3: 3 (25%) patients, TR4: 5 (16.1%), TR5: 9 (90%) patients, respectively.

CONCLUSION: The ACR TI-RADS score was statistically significant in predicting malignancy in AUS/FLUS patients whose follow-ups and treatments are controversial, and the ACR TI-RADS has a limited role in preventing unnecessary thyroidectomies in patients with AUS/FLUS.

KEYWORDS: Thyroid nodule. Thyroid neoplasms. Ultrasonography. Biopsy, fine-needle. Data systems.

INTRODUCTION
The incidence of thyroid cancer is increasing worldwide, and it is the most common cancer observed in the endocrine system1. An excellent prognosis is achieved with early diagnosis and surgery in thyroid malignancies2. Fine needle aspiration (FNA) cytology is a safe method that prevents unnecessary surgical procedures for a benign nodule3,4. In 2007, The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was proposed5. In TBSRTC, the third category has been defined as atypia of undetermined significance and follicular lesion of uncertain significance (AUS/FLUS) (BETHESDA 3). This category is a group of highly heterogeneous thyroid lesions with a high limit of cellularity. The “AUS/FLUS” category in TBSRTC caused controversy. The cases in this heterogeneous group include FNA

1Abant Izzet Baysal University Hospital, Department of General Surgery – Bolu, Turkey.
*Corresponding author: otuzogur@gmail.com
Conflicts of interest: the authors declare there are no conflicts of interest. Funding: none.
Received on December 29, 2020. Accepted on January 31, 2021.
The effect of ACR TI-RADS on AUS/FLUS patients

leads to confusion in patient management. Uncertainty in predicting the risk of malignancy in AUS/FLUS can be seen in the pathological results of patients operated on, which vary between 6 and 48%. When results of patients operated on are the same, FNA biopsy is repeated in patients whose FNAB results were preoperative USG findings. The FNA biopsy is not recommended, but the follow-up is recommended. In this approach, nodules with an ACR TI-RADS score of 3 (TR3) are less than 25 mm, the biopsy is not recommended. In addition, if mild suspect nodules are classified as Group 1, the age of the patients in Group 2 was 50.26 (SD 9.74) (p=0.96). When the gender distributions are examined, there was no statistically significant difference (p=0.26).

In the statistical analysis of ACR TI-RADS score between the groups, the ACR TI-RADS score (3.36) (SD 0.87) in Group 1 was significantly lower than the ACR TI-RADS score (4.11) (SD 1.04) in Group 2 patients (p=0.003) (Table 2). It was observed that there were statistical differences between Group 1 and Group 2 in composition (p=0.007), echogenicity (0.009), and the patients were scheduled for thyroidectomy. The patients whose control FNAB results were reported as AUS/FLUS and who performed thyroidectomy were included in this study. The postoperative pathological results were obtained. Thyroid USGs were performed by two radiologists who were blinded to the study. Grouping was made according to the result of postoperative pathology: those with benign results after postoperative pathology were classified as Group 1 and those with the malignant result after postoperative pathology were classified as Group 2. Patients were grouped based on histology. The intent is to predict malignancy with TI-RADS.

Statistics

Whether variables were normally distributed or not was checked by the Kolmogorov–Smirnov test. When applying a t-test for variables with normal distribution, the Mann–Whitney test was used for the analysis of variables that do not show normal distribution. A crosstabs test was used to correlate between the ACR TI-RADS groups and its subgroups. The chi-square test was used for gender analysis. All the analyses were performed with the Statistical Package for Social Sciences 25.0 for Windows (SPSS Inc., Chicago, IL, USA), and the results with a level of p<0.05 were considered to be statistically significant.

RESULTS

Preoperative USG was performed in accordance with the ACR TI-RADS scoring. A total of 66 patients with preoperative FNA cytology and AUS/FLUS were included in this study. When the patients were grouped according to the result of postoperative pathology, there were 47 patients in Group 1 and 19 patients in Group 2. The classification of the patients in the groups according to the postoperative pathological results is shown in Table 1. Of the 259 patients with preoperative FNA cytology, the results of 66 patients were found to be AUS/FLUS. This constitutes 25.48% of all biopsy results. This rate is higher than the rates in the literature (2.2–18%).

In the statistical analysis of the age values of 66 patients with AUS/FLUS according to the FNA cytology, the age of the patients in Group 1 was 47.51 (SD 9.54) and the age of the patients in Group 2 was 50.26 (SD 9.74) (p=0.96). When the gender distributions are examined, there was no statistically significant difference (p=0.26).

In the statistical analysis of ACR TI-RADS score between the groups, the ACR TI-RADS score (3.36) (SD 0.87) in Group 1 patients was significantly lower than the ACR TI-RADS score (4.11) (SD 1.04) in Group 2 patients (p=0.003) (Table 2). It was observed that there were statistical differences between Group 1 and Group 2 in composition (p=0.007), echogenicity (0.009), and

METHODS

In Bolu Abant Izzet Baysal University (B.A.I.B.U) General Surgery Clinic, case series between 2017 and 2020 were analyzed with thyroid operated. Preoperative USG, thyroid FNA cytology results, and postoperative pathological results were examined. The preoperative thyroid FNA cytology results, the patients who were operated on, and the preoperative USG results containing data (i.e., composition, echogenicity, AP/Transverse diameter, margin, and echogenic foci) suitable for ACR TI-RADS scoring were evaluated. Patients without preoperative FNA cytology results and ACR TI-RADS scoring in USG were excluded from this study. The ACR TI-RADS scores were obtained by calculating the ACR TI-RADS score of the nodule with the highest score in USG. The FNA biopsy (FNAB) was repeated in patients whose FNAB results were presented as AUS/FLUS, and when these results were the same,
margin (p=0.009) subgroups that form the basis of ACR TI-RADS scoring. However, there were no statistical differences between Group 1 and Group 2 in shape (p=0.165) and echogenic foci (p=0.935) subgroups that form the basis of ACR TI-RADS scoring.

The distribution of patients according to TI-RADS groups is as follows: TR2 had 13/66 (19.7%) patients, TR3 had 12/66 (18.2%) patients, TR4 had 31/66 (47%) patients, and TR5 had 10/66 (15.2%) patients. It was observed that the most patients were in the TR4 group and the least patients were in the TR5 group. Comparing the groups and ACR TI-RADS scores of 66 patients with Bethesda 3 scores, ACR TI-RADS distributions, and numbers of patients, respectively, TR2 had 11 (84.6%) patients in Group 1 and 2 (15.4%) patients in Group 2; TR3 had 9 (75%) patients in Group 1 and 3 (25%) patients in Group 2; TR4 had 26 (83.9%) patients in Group 1 and 5 (16.1%) patients in Group 2; TR5 had 1 (10%) patient in Group 1 and 9 (90%) patients in Group 2 (Table 3). Cancer rates are very close between TR2 (15.4) and TR4 (16.1) due to the high number of benign patients in the TR4 group.

When the ACR TI-RADS scores of 19 patients with malignant AUS/FLUS were evaluated according to the results of the postoperative pathology, no biopsy should have been performed in two patients in the TR2 category. According to the ACR TI-RADS algorithm, biopsies should not have been performed for three patients in the TR3 because the nodule sizes were below 2.5 cm. In the TR4 category, two patients whose nodule size was less than 1.5 cm should not have been biopsied and USG follow-up should have been performed. Thus, seven patients could not be diagnosed with thyroid cancer. In the TR5 category, FNAB was required according to the ACR TI-RADS system because the nodule sizes of all patients were above 1 cm.

### DISCUSSION

The follow-up and treatment of the results in the AUS/FLUS category are still controversial. While the average usage rate of AUS/FLUS ranges between 2.1 and 18% of all thyroid FNABs, the postoperative malignancy rate was reported to vary between 6 and 18% in AUS/FLUS.

It is aimed to exclude cases that do not clearly exhibit benign features with the AUS/FLUS category. AUS/FLUS is a heterogeneous category with various abnormal features, but it is assumed to be at low risk of malignancy. It also includes samples with cellularity on the limits/low quality. Nodules with AUS/FLUS are often resected if suspicious clinical and USG features are present and there are abnormal results in recurrent FNA cytology. Resection is not performed in patients who are reported as benign in recurrent FNA cytology. The USG of thyroid nodules is the most effective diagnostic tool to predict malignancy and select lesions that require further evaluation.

The USG–FNA cytology is the most cost-effective procedure that provides useful diagnostic information about advanced

### Table 1. Distribution of patients by pathological results.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Postoperative pathological results</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>Nodular adenomatous hyperplasia</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Follicular hyperplasia</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Nodular colloidal goiter</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Adenomatous nodule</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Lymphocytic thyroid</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Follicular adenoma</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Subacute lymphocytic thyroid</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Hurthle cell adenoma</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Hashimoto thyroiditis</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Cavernous hemangioma</td>
<td>1</td>
</tr>
<tr>
<td>Group 2</td>
<td>Papillary thyroid carcinoma</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Minimal invasive follicular carcinoma</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Papillary microcarcinoma</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)</td>
<td>1</td>
</tr>
</tbody>
</table>

### Table 2. Test results of American College of Radiology Thyroid Imaging, Reporting and Data System and subgroups.

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n=47)</th>
<th>Group 2 (n=19)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TI-RADS</td>
<td>3.36 SD 0.87</td>
<td>4.11 SD 1.04</td>
<td>0.003</td>
</tr>
<tr>
<td>Composition</td>
<td>1 (0–2)</td>
<td>1 (1–2)</td>
<td>0.007</td>
</tr>
<tr>
<td>Echogenicity</td>
<td>0 (0–3)</td>
<td>3 (0–3)</td>
<td>0.009</td>
</tr>
<tr>
<td>Shape</td>
<td>0 (0–2)</td>
<td>0 (0–2)</td>
<td>0.165</td>
</tr>
<tr>
<td>Margin</td>
<td>0.060 (0.03–0.15)</td>
<td>0.057 (0.03–0.10)</td>
<td>0.009</td>
</tr>
<tr>
<td>Echogenic foci</td>
<td>0 (0–3)</td>
<td>0 (0–3)</td>
<td>0.935</td>
</tr>
</tbody>
</table>

TI-RADS: Thyroid Imaging Reporting and Data System.
The effect of ACR TI-RADS on AUS/FLUS patients

The clinical and practical purpose of this diagnostic tool is to reduce the number of unnecessary surgical procedures in patients with benign nodules and to identify people at high risk of malignancy. While 47 of the 66 patients with AUS/FLUS in our study were benign as a result of post-operative pathology, 19 (28.78%) of the patients were reported as malignant. The rate of 28.78% that we reported was found to be higher than the rate of 6–18% AUS/FLUS malignancy, which is stated in the world literature.

There are many guidelines regarding the USG evaluation of thyroid nodules. Several USG-based methods were developed to classify the risk of malignancy of thyroid nodules in adults. Two of these methods are Kwak TI-RADS and ACR TI-RADS (which is officially stated by the ACR in 2017 for the management of thyroid nodules). ACR TI-RADS is based on evaluating the USG properties of nodules in five categories (i.e., composition, echogenicity, shape, shape, and echogenic foci) where each category is given 0–3 points. While each of the features in the first four categories has a single score derived from exclusive choices, there may be more than one feature in the echogenic foci category. In ACR TI-RADS, the scores are given for all USG features in a nodule, i.e., the more suspicious features get higher scores. In other words, the possibility of malignancy associated with each feature is weighted and considered differently. Along with the maximum diameter of the nodule, the TR level recommends that FNA cytology, follow-up by USG, or any other procedure should not be performed to the patient.

Total scores determine the level of ACR TI-RADS of the nodule, ranging from TR1 (benign) to TR5 (suspicious of high malignancy). Compliance with ACR TI-RADS will result in less benign nodule biopsy, as the threshold diameters for mild and moderately suspect nodules (TR3 and TR4) are larger than other systems. However, it will result in less malignant nodule cytology. Therefore, ACR TI-RADS recommends observation and following of some nodules that do not meet the size criteria for FNA cytology.

In our study, we showed that ACR TI-RADS was statistically significant in predicting malignancy in patients with AUS/FLUS. We concluded that unnecessary surgery can be prevented by the ACR TI-RADS assessment in patients with AUS/FLUS. Although it was statistically significant, when examined proportionally, it was observed that only TI-RADS appeared as a robust tool in predicting malignancy with only the TR5 group (90%), but this was not valid for other TR groups. Consequently, it was concluded that seven patients with AUS/FLUS, whose post-operative results were reported as malignant, could not be diagnosed. This number constitutes a high rate of 36.8% of 19 patients with AUS/FLUS who were malignant according to the results of pathology.

All of the patients were operated on by evaluating preoperative FNAB. This study has two limitations. One is that this is a retrospective study, and the other is that the number of cases is limited in our study.

CONCLUSION

The ACR TI-RADS score was statistically significant in predicting malignancy in AUS/FLUS patients whose follow-ups and treatments are controversial, and ACR TI-RADS has a limited role in preventing unnecessary thyroidectomies in patients with AUS/FLUS.

AUTHORS’ CONTRIBUTIONS

OC: Conceptualization, Data curation, Formal Analysis, Writing – original draft. MS: Writing – original draft, Writing – review & editing. BO: Data curation, Formal Analysis. HY: Data curation.
REFERENCES


